Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

This study indicated that by analyzing the data of one of the most extensive GA patient cohorts in the Nordic countries, it established a data set on the long-term treatment-naive GA growth dynamics.

A study reveals that lesion characteristics in geographic atrophy significantly influence growth rates, highlighting the need for targeted treatment strategies. The lesion characteristics of patients ...

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life.

Ashkan Abbey, MD, FASRS, FAAO, from Texas Retina Associates discussed EYP-1901, an innovative intravitreal insert that releases vorolanib, a potent tyrosine kinase inhibitor designed to treat retinal ...

Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.

While the STAR trial showed significant reductions in myopia progression, including over 50% in fast-progressing children, the FDA requires additional evidence to support US approval. Additionally, a ...

DURAVYU is being developed as a potential sustained-delivery treatment for patients suffering from serious retinal diseases. EyePoint Pharmaceuticals has released details for its pivotal phase 3 ...